Le Lézard
Classified in: Health
Subjects: CHI, SVY, AVO

Several In Utero Fluoride/IQ Studies Should Provoke A Nation-Wide Fluoridation Moratorium


NEW YORK, Aug. 30, 2019 /PRNewswire/ -- Critics of the fluoride-IQ study published this month in JAMA Pediatrics claimed it needed replication. However, the Canadian study by Green (2019) was already a replication of another U.S. government-funded study published in 2017 by Bashash which found similar effects, reports the Fluoride Action Network (FAN).

Both were Mother-Offspring studies that used urinary fluoride levels during pregnancy to assess cognition in the paired offspring. 

Both studies have shown a strong relationship between maternal exposure to fluoride and lowered IQ in offspring. Each revealed that the fetal stage appears to be the most vulnerable time period for fluoride's neurotoxicity.

Actually, FAN points out that there have been five studies that have found this relationship between maternal exposure and lowered IQ in children (see listing below). However, the Canadian study is the first to compare fluoridated vs non-fluoridated cities. The pregnant women in Canada with higher urinary fluoride levels had offspring with lower IQs and were from the fluoridated cities.

Paul Connett, PhD, FAN Executive Director, says, "For years promoters of fluoridation have argued that there is no harm from fluoridation; these and other studies indicate that there is potential harm and it is serious. It is unconscionable to continue fluoridation until this is resolved. For those who doubt the current findings more studies can be done once a moratorium on fluoridation is in place. To do otherwise is to condone a human experiment on millions of children."

Connett adds, "To ignore brain health and continue fluoridation in name of dental health is a huge disservice to the children of this country. FAN argues that there are more effective programs to reduce dental inequities (eg, 'Childsmile' in Scotland) and communities can easily implement them."

The Mother-Offspring studies, listed below, can be accessed at http://fluoridealert.org/issues/moms2b/mother-offspring-studies/

Green (2019). Largest study with 512 mother-offspring. Lower IQ in children 3- 4 years of age.

Bashash (2017). Longest study. 299 mother-offspring pairs in Mexico. Lower IQ in children 4 and 6-12 years of age.

Thomas (2018). 401 mother-offspring pairs in Mexico. Lower IQ in children 1-3 years of age Only the abstract has been published.

Valdez Jiménez (2017). Lower IQ between the ages of 3-15 months with 65 mother-offspring pairs in Mexico.

Li (2004). Significant differences in the neonatal behavioral neurological assessment score in 91 offspring aged 1-3 days old.

SOURCE Fluoride Action Network


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: